The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?

Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2004-03, Vol.40 (4), p.515-520
Hauptverfasser:	Delaunoit, Th, Ducreux, M., Boige, V., Dromain, C., Sabourin, J.-C., Duvillard, P., Schlumberger, M., de Baere, T., Rougier, P., Ruffie, P., Elias, D., Lasser, P., Baudin, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Follow-Up Studies Humans Male Medical sciences Middle Aged Neuroendocrine carcinoma Pancreas Pancreatic Neoplasms - drug therapy Pharmacology. Drug treatments Streptozocin - administration & dosage Streptozocin - adverse effects Survival Analysis Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!